{
  "question_stem": {
    "en": "After a confirmatory biopsy, treatment with rituximab infusion is planned. This medication is most likely to improve this patient's condition via which of the following mechanisms? {{exhibit_1}}",
    "zh": "在确诊活检后，计划进行利妥昔单抗输注治疗。该药物最有可能通过以下哪种机制改善患者的病情？ {{exhibit_1}}"
  },
  "question": {
    "en": "A 57-year-old woman comes to the emergency department due to cough and hemoptysis. The patient also reports several months of fatigue and joint pain. Physical examination is notable for crusting of the nasal mucosa, lung crackles, and scattered palpable purpura over the lower extremities. Chest x-ray reveals bilateral, diffuse alveolar infiltrates. Laboratory studies show normocytic anemia, red blood cell casts and protein in the urine, and positive c-ANCA.",
    "zh": "一名57岁女性因咳嗽和咯血来到急诊科。患者还报告了数月来疲劳和关节疼痛。体格检查显示鼻粘膜结痂、肺部啰音，以及下肢散在可触及的紫癜。胸部X线片显示双侧弥漫性肺泡浸润。实验室检查显示正细胞性贫血，尿中红细胞管型和蛋白，以及c-ANCA阳性。"
  },
  "options": {
    "A": {
      "en": "Blockade of T-cell costimulation",
      "zh": "阻断 T 细胞共刺激"
    },
    "B": {
      "en": "Depletion of B cells",
      "zh": "B 细胞耗竭"
    },
    "C": {
      "en": "Disruption of leukocyte migration",
      "zh": "破坏白细胞迁移"
    },
    "D": {
      "en": "Inhibition of cytoplasmic kinase",
      "zh": "抑制细胞质激酶"
    },
    "E": {
      "en": "Interruption of cytokine function",
      "zh": "中断细胞因子功能"
    }
  },
  "correct_answer": "B",
  "explanation": {
    "en": "This patient's clinical picture is consistent with granulomatosis with polyangiitis (GPA), a c-ANCA-positive inflammatory vasculitis that primarily attacks the upper/lower respiratory tract, kidneys, and skin. Molecular and immunologic advances have led to a dramatic expansion in treatments for chronic systemic inflammatory diseases such as GPA; treatments are generally classified as follows:\n\n*   Cytokine inhibitors: These bind free inflammatory cytokines or block cytokine receptors on cell surfaces; they target tumor necrosis factor (eg, infliximab, etanercept), IL-1, IL-6, IL-17, or IL-12/23 (Choice E).\n*   T-cell costimulation inhibitors: Two steps are required to activate cytotoxic T cells. The T cell must bind a specific antigen on the major histocompatibility complex type 1 of an antigen-presenting cell, and then the T cell must be costimulated by the interaction between the T-cell surface receptor CD28 and the antigen-presenting cell surface ligand CD80/86. T-cell costimulatory inhibitors (eg, abatacept) block the CD28 receptor on the cytotoxic T cell, which prevents T-cell costimulation and causes T-cell anergy (Choice A).\n*   B-cell depletion or inhibition: Because B cells generate inflammatory cytokines, promote T-cell activation, and differentiate into plasma cells that generate autoantibodies, medications that inhibit B-cell activation (eg, belimumab) or deplete B-cell populations (eg, rituximab) are highly effective in many systemic inflammatory disorders.\n\nRituximab is an IgG monoclonal antibody against CD20, a surface molecule present on developing and mature B cells. Binding of rituximab to CD20 results in Fc receptor-mediated B-cell cytotoxicity and antibody-dependent B-cell phagocytosis, which significantly reduces the B-cell population. Although existing plasma cells are unaffected (they do not express CD20), the reduction in total B-cell population significantly improves inflammatory symptoms. However, depletion of B cells also increases the risk for severe and recurrent bacterial infections, a major adverse effect of therapy.\n\n(Choice C) Natalizumab is a monoclonal antibody against integrin, an adhesion molecule that mediates leukocyte interaction with the endothelium and subsequent leukocyte attachment/migration into tissue. Natalizumab is used in relapsing-remitting multiple sclerosis.\n\n(Choice D) Cytoplasmic kinases (eg, Janus kinase) transmit inflammatory cytokine receptor binding to the nucleus. Rituximab does not operate via this mechanism, but new therapies that target these intracellular signaling pathways are under development.",
    "zh": "该患者的临床表现与肉芽肿性多血管炎（GPA）一致，这是一种 c-ANCA 阳性炎症性血管炎，主要攻击上/下呼吸道、肾脏和皮肤。分子和免疫学进展导致了慢性全身性炎症性疾病（如 GPA）治疗的显着扩展；治疗方法通常分为以下几类：\n\n*   细胞因子抑制剂：这些药物结合游离的炎症细胞因子或阻断细胞表面的细胞因子受体；它们靶向肿瘤坏死因子（如英夫利昔单抗、依那西普）、IL-1、IL-6、IL-17 或 IL-12/23（选项 E）。\n*   T 细胞共刺激抑制剂：激活细胞毒性 T 细胞需要两个步骤。 T 细胞必须结合抗原呈递细胞主要组织相容性复合物 1 型上的特定抗原，然后 T 细胞必须通过 T 细胞表面受体 CD28 和抗原呈递细胞表面配体 CD80/86 之间的相互作用来共刺激。 T 细胞共刺激抑制剂（例如，阿巴西普）阻断细胞毒性 T 细胞上的 CD28 受体，从而阻止 T 细胞共刺激并导致 T 细胞无能（选项 A）。\n*   B 细胞耗竭或抑制：由于 B 细胞产生炎症细胞因子，促进 T 细胞活化，并分化为产生自身抗体的浆细胞，因此抑制 B 细胞活化（例如，贝利单抗）或耗竭 B 细胞群（例如，利妥昔单抗）的药物在许多全身性炎症性疾病中非常有效。\n\n利妥昔单抗是一种针对 CD20 的 IgG 单克隆抗体，CD20 是一种存在于发育中和成熟 B 细胞上的表面分子。利妥昔单抗与 CD20 的结合会导致 Fc 受体介导的 B 细胞细胞毒性和抗体依赖性 B 细胞吞噬作用，这显着减少了 B 细胞群。尽管现有的浆细胞不受影响（它们不表达 CD20），但总 B 细胞群的减少显着改善了炎症症状。然而，B 细胞耗竭也会增加严重和复发性细菌感染的风险，这是治疗的主要不良反应。\n\n（选项 C）那他珠单抗是一种针对整合素的单克隆抗体，整合素是一种介导白细胞与内皮细胞相互作用，以及随后的白细胞附着/迁移到组织的粘附分子。那他珠单抗用于复发缓解型多发性硬化症。\n\n（选项 D）细胞质激酶（例如，Janus 激酶）将炎症细胞因子受体结合传递到细胞核。利妥昔单抗不通过这种机制起作用，但针对这些细胞内信号通路的的新疗法正在开发中。"
  },
  "summary": {
    "en": "The patient has granulomatosis with polyangiitis (GPA), and rituximab is being used for treatment. Rituximab is an IgG monoclonal antibody against CD20 on B cells, leading to B-cell depletion and reduced inflammation.",
    "zh": "患者患有肉芽肿性多血管炎（GPA），并正在使用利妥昔单抗进行治疗。利妥昔单抗是一种针对 B 细胞上 CD20 的 IgG 单克隆抗体，导致 B 细胞耗竭和炎症减轻。"
  },
  "tags": [
    "Immunology",
    "Allergy & Immunology",
    "Biologic agents"
  ],
  "exhibits": [
    {
      "id": "exhibit_1",
      "url": null
    }
  ],
  "category": "Immunology",
  "question_id": "20781",
  "has_exhibits": true,
  "exhibit_count": 1,
  "exhibit_files": [
    "image1.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Immunology 23\\20781",
  "extracted_at": "2025-11-05T14:44:39.896565",
  "extraction_config": {
    "temperature": 0.3,
    "top_k": 20,
    "prompt_strategy": "minimal"
  },
  "translated_at": "2025-11-07T18:01:52.365922",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}